1. Home
  2. HQY vs MDGL Comparison

HQY vs MDGL Comparison

Compare HQY & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HQY
  • MDGL
  • Stock Information
  • Founded
  • HQY 2002
  • MDGL 2011
  • Country
  • HQY United States
  • MDGL United States
  • Employees
  • HQY N/A
  • MDGL N/A
  • Industry
  • HQY Business Services
  • MDGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • HQY Consumer Discretionary
  • MDGL Health Care
  • Exchange
  • HQY Nasdaq
  • MDGL Nasdaq
  • Market Cap
  • HQY 8.7B
  • MDGL 7.1B
  • IPO Year
  • HQY 2014
  • MDGL N/A
  • Fundamental
  • Price
  • HQY $84.52
  • MDGL $301.66
  • Analyst Decision
  • HQY Strong Buy
  • MDGL Buy
  • Analyst Count
  • HQY 12
  • MDGL 10
  • Target Price
  • HQY $111.75
  • MDGL $354.75
  • AVG Volume (30 Days)
  • HQY 1.3M
  • MDGL 317.2K
  • Earning Date
  • HQY 06-02-2025
  • MDGL 05-06-2025
  • Dividend Yield
  • HQY N/A
  • MDGL N/A
  • EPS Growth
  • HQY 70.31
  • MDGL N/A
  • EPS
  • HQY 1.09
  • MDGL N/A
  • Revenue
  • HQY $1,199,774,000.00
  • MDGL $180,133,000.00
  • Revenue This Year
  • HQY $9.60
  • MDGL $228.41
  • Revenue Next Year
  • HQY $10.04
  • MDGL $73.44
  • P/E Ratio
  • HQY $77.54
  • MDGL N/A
  • Revenue Growth
  • HQY 20.03
  • MDGL N/A
  • 52 Week Low
  • HQY $65.01
  • MDGL $189.00
  • 52 Week High
  • HQY $115.59
  • MDGL $377.46
  • Technical
  • Relative Strength Index (RSI)
  • HQY 45.17
  • MDGL 40.18
  • Support Level
  • HQY $77.84
  • MDGL $292.49
  • Resistance Level
  • HQY $84.38
  • MDGL $330.64
  • Average True Range (ATR)
  • HQY 4.49
  • MDGL 20.56
  • MACD
  • HQY 0.78
  • MDGL -1.56
  • Stochastic Oscillator
  • HQY 70.28
  • MDGL 22.48

About HQY HealthEquity Inc.

HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Share on Social Networks: